AU2014306959B2 - Methods for increasing forced expiratory volume in asthmatics using benralizumab - Google Patents

Methods for increasing forced expiratory volume in asthmatics using benralizumab Download PDF

Info

Publication number
AU2014306959B2
AU2014306959B2 AU2014306959A AU2014306959A AU2014306959B2 AU 2014306959 B2 AU2014306959 B2 AU 2014306959B2 AU 2014306959 A AU2014306959 A AU 2014306959A AU 2014306959 A AU2014306959 A AU 2014306959A AU 2014306959 B2 AU2014306959 B2 AU 2014306959B2
Authority
AU
Australia
Prior art keywords
methods
benralizumab
asthmatics
expiratory volume
forced expiratory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014306959A
Other languages
English (en)
Other versions
AU2014306959A1 (en
Inventor
Donald Raible
Lorin Roskos
Bing Wang
Christine Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2014306959A1 publication Critical patent/AU2014306959A1/en
Assigned to ASTRAZENECA AB reassignment ASTRAZENECA AB Request for Assignment Assignors: MEDIMMUNE, LLC
Application granted granted Critical
Publication of AU2014306959B2 publication Critical patent/AU2014306959B2/en
Priority to AU2020201277A priority Critical patent/AU2020201277A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Endocrinology (AREA)
AU2014306959A 2013-08-12 2014-08-07 Methods for increasing forced expiratory volume in asthmatics using benralizumab Active AU2014306959B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020201277A AU2020201277A1 (en) 2013-08-12 2020-02-21 Methods for increasing forced expiratory volume in asthmatics using benralizumab

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361864948P 2013-08-12 2013-08-12
US61/864,948 2013-08-12
PCT/US2014/050119 WO2015023507A2 (en) 2013-08-12 2014-08-07 Methods for increasing forced expiratory volume in asthmatics using benralizumab

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020201277A Division AU2020201277A1 (en) 2013-08-12 2020-02-21 Methods for increasing forced expiratory volume in asthmatics using benralizumab

Publications (2)

Publication Number Publication Date
AU2014306959A1 AU2014306959A1 (en) 2016-02-04
AU2014306959B2 true AU2014306959B2 (en) 2019-11-21

Family

ID=52448838

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014306959A Active AU2014306959B2 (en) 2013-08-12 2014-08-07 Methods for increasing forced expiratory volume in asthmatics using benralizumab
AU2020201277A Abandoned AU2020201277A1 (en) 2013-08-12 2020-02-21 Methods for increasing forced expiratory volume in asthmatics using benralizumab

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020201277A Abandoned AU2020201277A1 (en) 2013-08-12 2020-02-21 Methods for increasing forced expiratory volume in asthmatics using benralizumab

Country Status (26)

Country Link
US (1) US9441046B2 (enExample)
EP (4) EP3520811B1 (enExample)
JP (4) JP6746496B2 (enExample)
KR (1) KR102337599B1 (enExample)
CN (2) CN111588849A (enExample)
AU (2) AU2014306959B2 (enExample)
BR (1) BR112016002317A8 (enExample)
CA (1) CA2917603C (enExample)
CY (2) CY1122033T1 (enExample)
DK (2) DK3033104T3 (enExample)
ES (2) ES2866426T3 (enExample)
HK (1) HK1222559A1 (enExample)
HR (2) HRP20190920T1 (enExample)
HU (2) HUE043497T2 (enExample)
LT (2) LT3033104T (enExample)
ME (1) ME03403B (enExample)
MX (2) MX381102B (enExample)
PL (2) PL3033104T3 (enExample)
PT (2) PT3033104T (enExample)
RS (2) RS58711B1 (enExample)
RU (1) RU2703568C2 (enExample)
SG (1) SG11201600483QA (enExample)
SI (2) SI3033104T1 (enExample)
SM (2) SMT202100152T1 (enExample)
TR (1) TR201907907T4 (enExample)
WO (1) WO2015023507A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015023504A1 (en) 2013-08-12 2015-02-19 Medlmmune, Llc Methods for reducing exacerbation rates of asthma using benralizumab
MX368474B (es) 2013-08-12 2019-10-04 Astrazeneca Ab Uso de benralizumab para mejorar síntomas de asma.
SG10201807318RA (en) * 2013-10-15 2018-09-27 Astrazeneca Ab Methods for treating chronic obstructive pulmonary disease using benralizumab
EP3892288A1 (en) * 2013-10-24 2021-10-13 Astrazeneca AB Stable, aqueous antibody formulations
TW202110479A (zh) * 2019-05-16 2021-03-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法
TW202126688A (zh) * 2019-09-27 2021-07-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療遲發性氣喘之方法
TW202214692A (zh) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013066780A2 (en) * 2011-11-01 2013-05-10 Medimmune, Llc Methods for reducing the frequency and severity of acute exacerbations of asthma

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6018032A (en) 1995-09-11 2000-01-25 Kyowa Hakko Kogyo Co., Ltd. Antibody against human interleukin-5-receptor α chain
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
CA2369292C (en) 1999-04-09 2010-09-21 Kyowa Hakko Kogyo Co. Ltd. Method of modulating the activity of functional immune molecules
CA2402477A1 (en) 2000-02-15 2001-08-23 Kyowa Hakko Kogyo Co., Ltd. Eosinophil-specific apoptosis inducer
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20070148170A1 (en) 2005-10-03 2007-06-28 Desjarlais John R Fc Variants With Optimized Fc Receptor Binding Properties
AU2004279740A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Antibody composition specifically binding to IL-5 receptor
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
DK3072525T3 (en) * 2007-05-14 2018-04-30 Astrazeneca Ab PROCEDURES FOR REDUCING BASOFILE CELL LEVELS
RU2383345C1 (ru) * 2008-08-07 2010-03-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") Способ лечения больных бронхиальной астмой
KR101615474B1 (ko) * 2010-12-16 2016-04-25 제넨테크, 인크. Th2 억제에 관한 진단 및 치료
CN102544908B (zh) 2010-12-17 2016-01-06 富士康(昆山)电脑接插件有限公司 电连接器组件及插头连接器
US8961965B2 (en) * 2011-05-18 2015-02-24 Medimmune, Llc Methods of diagnosing and treating pulmonary diseases or disorders
MX368474B (es) 2013-08-12 2019-10-04 Astrazeneca Ab Uso de benralizumab para mejorar síntomas de asma.
WO2015023504A1 (en) 2013-08-12 2015-02-19 Medlmmune, Llc Methods for reducing exacerbation rates of asthma using benralizumab

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013066780A2 (en) * 2011-11-01 2013-05-10 Medimmune, Llc Methods for reducing the frequency and severity of acute exacerbations of asthma

Also Published As

Publication number Publication date
ES2733602T3 (es) 2019-12-02
EP3033104A2 (en) 2016-06-22
RU2016108809A (ru) 2017-09-18
TR201907907T4 (tr) 2019-06-21
CN111588849A (zh) 2020-08-28
MX381102B (es) 2025-03-12
JP2022120010A (ja) 2022-08-17
LT3033104T (lt) 2019-06-25
JP6746496B2 (ja) 2020-08-26
PT3520811T (pt) 2021-03-15
JP2020125304A (ja) 2020-08-20
KR20160043049A (ko) 2016-04-20
MX2021003826A (es) 2021-05-27
HK1225300A1 (en) 2017-09-08
HUE053627T2 (hu) 2021-07-28
EP3520811A1 (en) 2019-08-07
CY1124399T1 (el) 2022-07-22
BR112016002317A2 (pt) 2017-12-12
KR102337599B1 (ko) 2021-12-10
SMT201900311T1 (it) 2019-07-11
AU2020201277A1 (en) 2020-03-12
EP4579236A3 (en) 2025-09-17
PL3033104T3 (pl) 2019-09-30
DK3520811T3 (da) 2021-03-22
HUE043497T2 (hu) 2019-08-28
US9441046B2 (en) 2016-09-13
WO2015023507A2 (en) 2015-02-19
EP3520811B1 (en) 2020-12-30
HRP20190920T1 (hr) 2019-07-12
CA2917603C (en) 2023-05-16
JP2016527325A (ja) 2016-09-08
EP4579236A2 (en) 2025-07-02
ME03403B (me) 2020-01-20
EP4636400A2 (en) 2025-10-22
EP3033104A4 (en) 2017-03-22
RU2016108809A3 (enExample) 2018-06-18
SMT202100152T1 (it) 2021-05-07
WO2015023507A3 (en) 2015-04-09
CY1122033T1 (el) 2020-10-14
EP3875487A1 (en) 2021-09-08
SG11201600483QA (en) 2016-02-26
EP3033104B1 (en) 2019-04-03
US20150044203A1 (en) 2015-02-12
WO2015023507A8 (en) 2015-09-24
CA2917603A1 (en) 2015-02-19
HK1222559A1 (zh) 2017-07-07
MX2016001384A (es) 2016-08-03
HRP20210406T1 (hr) 2021-04-30
AU2014306959A1 (en) 2016-02-04
PT3033104T (pt) 2019-06-27
BR112016002317A8 (pt) 2018-06-12
RS58711B1 (sr) 2019-06-28
RS61565B1 (sr) 2021-04-29
ES2866426T3 (es) 2021-10-19
DK3033104T3 (da) 2019-06-17
RU2703568C2 (ru) 2019-10-21
PL3520811T3 (pl) 2021-08-02
SI3033104T1 (sl) 2019-06-28
LT3520811T (lt) 2021-03-25
CN105451769A (zh) 2016-03-30
JP2024129140A (ja) 2024-09-26
SI3520811T1 (sl) 2021-04-30

Similar Documents

Publication Publication Date Title
EP3061326A4 (en) Hybrid generators and methods of using them
AU2014306959B2 (en) Methods for increasing forced expiratory volume in asthmatics using benralizumab
EP3730615A3 (en) Methods and compositions for treatment of a genetic condition
MX2019003616A (es) Celulas beta derivadas de celulas madre (sc-beta) y composiciones y metodos para generarlas.
IN2014DN03477A (enExample)
EP2898259B8 (en) Variable-beam light source and related methods
EP3063262A4 (en) Devices and methods for three-dimensional tissue culturing
UY4167Q (es) Par de auriculares
TWD174059S (zh) 速克達摩托車
EP3065875A4 (en) Bioprinter and methods of using same
EP3114077A4 (en) Methods of producing hydrogen and solid carbon
TWD166111S (zh) 速克達摩托車
TWD171869S (zh) 速克達摩托車
MY168394A (en) Apparatus and Method of Using the Same
EP3035521A4 (en) Power generating apparatus
EP2992528A4 (en) Hybrid encoding of multichannel audio
EP3014628B8 (en) Process of generating germanium-68
AU2014205587A8 (en) SHIP1 modulators and methods related thereto
EP3052634A4 (en) Compositions and methods for modulating biomass productivity
BR112014027219A2 (pt) método
MY167584A (en) Method for producing ethanol
EP3033103A4 (en) Methods for improving asthma symptoms using benralizumab
WO2014146111A3 (en) Analgesic compounds and methods of use
EP3003325A4 (en) Methods of evaluating cell culture additives
EP3066261A4 (en) Creping adhesives and methods for making and using same

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ASTRAZENECA AB

Free format text: FORMER APPLICANT(S): MEDIMMUNE, LLC

FGA Letters patent sealed or granted (standard patent)